About 4 results found for searched term "Rituximab" (0.126 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M6219 | Rituximab | CD20 |
| IDEC-C2B8 | ||
| Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD. | ||
| M24744 | Laprituximab emtansine | EGFR/HER2 |
| IMGN-289; J2898A-SMCC-DM1 | ||
| Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research. | ||
| M24745 | Laprituximab | EGFR/HER2 |
| J2898A | ||
| Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289. | ||
| M25295 | Urelumab | Others |
| Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab. Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
